Obi, Kisho Amano, Izuki and Takatsuru, Yusuke 2018. Role of dopamine on functional recovery in the contralateral hemisphere after focal stroke in the somatosensory cortex. Brain Research, Vol. 1678, p. 146.
Yoshinaga, Hidefumi Nishida, Tomoaki Sasaki, Izumi Kato, Taro Oki, Hitomi Yabuuchi, Kazuki and Toyoda, Tomohiro 2018. Discovery of DSP-1053, a Novel Benzylpiperidine Derivative with Potent Serotonin Transporter Inhibitory Activity and Partial 5-HT 1A Receptor Agonistic Activity. Bioorganic & Medicinal Chemistry,
Ganella, Eleni P. Bartholomeusz, Cali F. Seguin, Caio Whittle, Sarah Bousman, Chad Phassouliotis, Christina Everall, Ian Pantelis, Christos and Zalesky, Andrew 2017. Functional brain networks in treatment-resistant schizophrenia. Schizophrenia Research, Vol. 184, p. 73.
Recio, Rocío Vengut-Climent, Empar Mouillac, Bernard Orcel, Hélène López-Lázaro, Miguel Calderón-Montaño, José Manuel Álvarez, Eleuterio Khiar, Noureddine and Fernández, Inmaculada 2017. Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4 H -pyran core: Switch from antagonist to agonist effect by chemical modification. European Journal of Medicinal Chemistry, Vol. 138, p. 644.
Yoshinaga, Hidefumi Masumoto, Shuji Koyama, Koji Kinomura, Naoya Matsumoto, Yuji Kato, Taro Baba, Satoko Matsumoto, Kenji Horisawa, Tomoko Oki, Hitomi Yabuuchi, Kazuki and Kodo, Toru 2017. Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT1A weak partial agonistic activity showing the antidepressant-like effect. Bioorganic & Medicinal Chemistry, Vol. 25, Issue. 1, p. 293.
Murphy, Anna Dursun, Serdar McKie, Shane Elliott, Rebecca and Deakin, John Francis William 2016. An investigation into aripiprazole’s partial D2 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. Psychopharmacology, Vol. 233, Issue. 8, p. 1415.
Citrome, Leslie Stensbøl, Tine Bryan and Maeda, Kenji 2015. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?. Expert Review of Neurotherapeutics, Vol. 15, Issue. 10, p. 1219.
Fan, X. Borba, C. P. C. Copeland, P. Hayden, D. Freudenreich, O. Goff, D. C. and Henderson, D. C. 2013. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatrica Scandinavica, Vol. 127, Issue. 3, p. 217.
Oates, Francesca and Siddiqui, Fouad 2012. Drug-induced movement disorders. Adverse Drug Reaction Bulletin, Vol. 275, Issue. 1, p. 1059.
Natesan, Sridhar Reckless, Greg E. Barlow, Karen B. L. Nobrega, José N. and Kapur, Shitij 2011. Partial agonists in schizophrenia – why some work and others do not: insights from preclinical animal models. The International Journal of Neuropsychopharmacology, Vol. 14, Issue. 09, p. 1165.
Takami, Goro Ota, Miyuki Nakashima, Akira Kaneko, Yoko S. Mori, Keiji Nagatsu, Toshiharu and Ota, Akira 2010. Effects of atypical antipsychotics and haloperidol on PC12 cells: only aripiprazole phosphorylates AMP-activated protein kinase. Journal of Neural Transmission, Vol. 117, Issue. 10, p. 1139.
Thompson, Judy L Urban, Nina and Abi-Dargham, Anissa 2009. How have developments in molecular imaging techniques furthered schizophrenia research?. Imaging in Medicine, Vol. 1, Issue. 2, p. 135.
Newman-Tancredi, Adrian Heusler, Peter Martel, Jean-Claude Ormière, Anne-Marie Leduc, Nathalie and Cussac, Didier 2008. Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors: G-protein activation and K+ channel modulation in transfected cells. The International Journal of Neuropsychopharmacology, Vol. 11, Issue. 03,
Nordquist, R.E. Risterucci, C. Moreau, J.L. von Kienlin, M. Künnecke, B. Maco, M. Freichel, C. Riemer, C. and Spooren, W. 2008. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology, Vol. 54, Issue. 2, p. 405.
Nasrallah, H A 2008. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Molecular Psychiatry, Vol. 13, Issue. 1, p. 27.
Plaze, M. 2008. Comprendre les effets latéraux des antipsychotiques atypiques. L'Encéphale, Vol. 34, p. S237.
Jarboe, Kathleen S. 2007. Considering the Impact on Overall Patient Health When Choosing Antipsychotic Therapy. Journal of the American Psychiatric Nurses Association, Vol. 13, Issue. 5_suppl, p. S23.
Wadenberg, Marie-Louise G 2007. Bifeprunox: a novel antipsychotic agent with partial agonist properties at dopamine D2 and serotonin 5-HT1Areceptors. Future Neurology, Vol. 2, Issue. 2, p. 153.
Karunakaran, Kanapathippillai Tungaraza, Tongeji E. and Harborne, Giles C. 2007. Is clozapine—aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?. Journal of Psychopharmacology, Vol. 21, Issue. 4, p. 453.
Urban, Jonathan D Vargas, Gabriel A von Zastrow, Mark and Mailman, Richard B 2007. Aripiprazole has Functionally Selective Actions at Dopamine D2 Receptor-Mediated Signaling Pathways. Neuropsychopharmacology, Vol. 32, Issue. 1, p. 67.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.
Full text views reflects the number of PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
* Views captured on Cambridge Core between 3rd January 2018 - 19th March 2018. This data will be updated every 24 hours.